A live oral cholera vaccine VA @ developed from a non-toxigenic Vibrio cholerae O@ El Tor strain using ctxB gene insertion was further developed into a clinical product following cGMP and was evaluated in a double-blind randomized placebo controlled parallel group two arm trial with allocation ratio of @ for safety and immunogenicity in men and women aged @-@ years from Kolkata , India .